Most Recent
AFT Pharmaceuticals has accused rival Reckitt Benckiser of using the court as a "clearance house" to beat its competitors, the latest development in a long-running dispute over AFT's Maxigesic ads.
Electricity retailer Click Energy has been ordered to pay $900,000 in penalties for misleading consumers about discounts on their energy bills.
Pharmaceutical giant Mylan has been ordered to hand over documents relating to its proposed launch of a generic version of its cholesterol drug Lipidil to rival Sun Pharma in advance of a hearing on Mylan's request for an order blocking Sun from launching its own generic version of the drug.
Generic pharmaceutical firm Sandoz has won a temporary stay of a $26.3 million judgment in a patent case as it awaits a decision by the Commissioner of Patents regarding a licence to make a cheaper version of the bestselling antidepressant Lexapro.
Industry group Meat & Livestock Australia is challenging a ruling allowing US company Branhaven's cow genome patent to proceed, after a judge called the group's challenge to Branhaven's amendments to the patent "bizarre" and "flimsy".
Deloitte Touche Tohmatsu is facing claims by the lead applicants in two class actions against failed retail giant Dick Smith alleging its poor accounting practices contributed to the retailer's collapse.
The founder of JustKapital is considering adding Corrs Chambers Westgarth to a lawsuit he brought seeking nearly $1 million allegedly owed as part of a deal he made to step down as managing director from the litigation funder.
An appeals court has overturned a ruling awarding $2 million in compensation to United Petroleum after the state government compulsorily acquired land on which the petrol retailer operated a service station and restaurant.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
AFT Pharmaceuticals has agreed to a court order temporarily restraining it from distributing point of sale material containing updated claims that its painkiller Maxigesic is more effective than other over-the-counter medications.